EMCDDA Conference Lisbon 6-8 May 2009 Treatment and Harm Reduction in Prison and Continuity of Care Caren Weilandt WIAD (Scientific Institute of the German.

Slides:



Advertisements
Similar presentations
TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM.
Advertisements

Training Criminal Justice Professionals in Harm Reduction Services for Vulnerable Groups funded by the European Commissions Directorate General for Health.
Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.
HIV in Europe Stockholm, 3.November 2009 Communication on combating HIV/AIDS in the EU and the neighbourhood - strategy and second action plan ( )
Workshop IV: Provision of Health Care The Impact of International Standards and Guidelines on prisoner health in Eastern and Central Europe Antalya, Turkey.
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Turning the tide: Not without prisons! Promoting comprehensive national HIV responses.
The Health in Prisons Programme HIPP of WHO Why does WHO engage in prison health?
Needle and syringe programmes in prisons
GAP Report 2014 Prisoners People left behind: Prisoners Link with the pdf, Prisoners.
A Call for Action HIV/AIDS & Hepatitis C in Irish Prisons Irish Penal Reform Trust & Merchants Quay Ireland by Rick Lines, MA July 26, 2002.
© Aahung 2004 Millennium Development Goals Expanding the Agenda:
Harm Reduction and Drug Policy in Western European Prisons “HIV, Hepatitis C, and Harm Reduction in prisons: Evidence, Best Practice and Human Rights“
Operational Approaches for Comprehensive Sex Worker Programmes An overview of Implementing Comprehensive HIV/STI Programmes with Sex Workers: Practical.
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Drug use, related problems and interventions targeting drug users in prison in the European countries: main issues and challenges for the future Linda.
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
Steven Shoptaw, PhD UCLA Department of Family Medicine Center for Behavioral and Addiction Medicine A DRAFT PACKAGE OF INTERVENTIONS.
HIV AIDS Section Fabienne Hariga Senior Adviser UNODC HIV AIDS section, Vienna Comprehensive package of interventions for HIV in prison settings AIDS 2012.
Dr Fabienne Hariga Senior Adviser UNODC HIV Section, Vienna 27 May 2014 Mandates, missions, roles and responsibilities & relation to health in prisons.
Departmental Perspectives on Viral Hepatitis
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
 Insufficient Reliable data in this region  Estimated people living with HIV  The number of new HIV infections in the region increased.
Part 2 Gender and HIV/AIDS HIV/AIDS IS A GENDER ISSUE BECAUSE: I Although HIV effects both men and women, women are more vulnerable because of biological,
HIV/AIDS in Prison Settings Dr. Monica Beg HIV/AIDS Unit, United Nations Office on Drugs and Crime, Krakow, Poland September 27, 2004.
Guidance on Provider-initiated Voluntary Medical Examination, Testing and Counselling for Infectious Diseases in Injecting Drug Users Hans Blystad 1 and.
HIV and drug prevention in Estonia Harm reduction services
Treatment of drug addiction in prisons
Municipal Drug Policy Legislation, institutions and programs Assoc. Prof. Hristo Bozov, MD, PhD Deputy-Mayor of Municipality of Varna Chairman of Municipal.
Quality Assurance at the European Monitoring Centre for Drugs and Drug Addiction Sandrine Sleiman European Conference on Quality in Official Statistics,
Harm Reduction.
At the frontier of drug harm reduction Prisoners’ rights to health & safety David McDonald Visiting Fellow National Centre for Epidemiology and Population.
Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
Jennifer Hillebrand, „Rehabilitation of Drug Addicted Persons: Experience of Lithuania and European Countries”, 18 October 2007 Improving drug treatment.
Recommendations on the Management of Opioid Overdose Ruth Birgin.
Results from the Spanish experience: A comprehensive approach to HIV and HCV in prisons MERCEDES GALLIZO LLAMAS Secretary-General of Spanish Prison Administration.
HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.
 To what extent is IMCI implemented in NWP and what are the obstacles to its implementation?  What is the impact of IMCI in NWP?  What is the impact.
HIV/AIDS BI-ANNUAL REVIEW 2008 Prevention -Goal, Indicators and Targets TACAIDS.
Safe Immunization Practices and Prevention of Hepatitis B and C Susan Mackay Behaviour Change Project Safe Injection Global Network.
If I ruled the world… Presentation to Prisons and Beyond NOMS Prison Drug Strategy Unit, in association with the Federation of Drug & Alcohol Professionals.
Washington D.C., USA, July 2012www.aids2012.org Human rights as a key component of harm reduction strategy targeting people using drugs in Morocco.
Module 7: Physical Health Needs Assessment. Objectives To understand the concept of harm minimisation. To be aware of the physical risks involved in drug.
EMCDDA Work Programme Key Issue 1: Key Indicators 30th Meeting of Scientific Committee J Vicente (together with D Olszewski, D Klempova, L Montanari,
„ Roma and Drugs in Figures – the Czech Republic“ Budapest, October 2004 Czech National Focal Point for Drugs and Drug Addiction Office of the Government.
Harm Reduction International
Overview of EMCDDA’s 2009 Scientific Work Programme Paul Griffiths, Roland Simon - REITOX Meeting, Lisbon, November 2007.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
HIV Prevention, Treatment and Care in Prisons and other Closed Settings Ehab Salah Prisons and HIV Advisor UNODC, Vienna ICASA 2015 Harare, Zimbabwe 2.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
1 NTA More treatment, better treatment, fairer treatment National injecting conference Annette Dale-Perera Director of Quality.
19 June 2007 Prison & Health Expert Meeting Paris Drugs and prisons DG SANCO C4 N. GRENIER.
From evidence to commitment to action: implementing HIV prevention measures in prisons in Ukraine XVI International AIDS Conference Toronto, 15 August.
NDPHS Expert Group on HIV/AIDS and Associated Infections Draft problem tree 5 December, 2011 Chair Dr. Ali Arsalo and ITA Ms Outi Karvonen.
The Canadian Correctional Public Health Program Prison Health Expert Group Sixth Meeting Oslo, Norway September 30, 2008.
Health in Prisons Project Oslo, 24 November 2009 Lars Moller Regional Adviser a.i. World Health Organization Regional Office for Europe Health in Prisons.
EG HIV/AIDS & AI Internal Strategy and Action Plan Country priorities according to a survey in January-February 2014.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Riga, 29 May 2008 Sintija Šmite, UNODC.
SUBSTITUTION TREATMENT IN THREE PORTUGUESE PRISONS M.J. Campos*; L. Fernandes**; J. Almeida*; L. Mendão*; R. Freitas* GAT – Grupo Português de Activistas.
Dr. Monica Beg, Chief, HIV/AIDS Section, UNODC
Fabienne Hariga Senior Adviser, HIV/AIDS Section
Government of Swaziland
Addressing Drug Use Together Through a Health Based Approach:
WHO minimum public health data set on prison health
Nisa, A.*, Carvalho, H*#, Castro, D*., Carvalhinho, S.*
The role of standards on quality of treatment of drug use
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Towards a Conducive Legal and Structural Environment
Presentation transcript:

EMCDDA Conference Lisbon 6-8 May 2009 Treatment and Harm Reduction in Prison and Continuity of Care Caren Weilandt WIAD (Scientific Institute of the German Medical Association), Bonn

EMCDDA Conference Lisbon 6-8 May 2009 EC Experts’ Report on Prevention, Treatment, and Harm Reduction Services in Prison pulished November 2008 Consortium (WIAD, Bonn, University Bremen and Centre for Interdisciplinary Addiction Research, Hamburg) The full report is available at EC and other webpages

Acknowledgements  Heino Stöver, Bremen Institute for Drug Research (BISDRO), University of Bremen  Doris Radun, Robert Koch-Institute, Berlin  Christina Hartwig, Centre for Interdisciplinary Addiction Research (CIAR), University of Hamburg  Katja Thane, Centre for Interdisciplinary Addiction Research (CIAR), University of Hamburg  Heike Zurhold, Centre for Interdisciplinary Addiction Research (CIAR), University of Hamburg

EMCDDA Conference Lisbon 6-8 May 2009 Methodology  Search –Databases, publications –National reports EMCDDA focal points –WHO Europe, Pompidou group, UNAIDS, UNODC –Contacts to national and international experts

EMCDDA Conference Lisbon 6-8 May 2009 Prison background data  600,000 prisoners, approx. 2 Mio per year  Average 121 per 100,000 (56 Slo-337Est)  Increasing number of prisoners in many countries; esp. female prisoners  Average 5% female  8-35% migrants  Overcrowding: average prison density 109

EMCDDA Conference Lisbon 6-8 May 2009 Prison density per 100 places

EMCDDA Conference Lisbon 6-8 May 2009 Sentenced prisoners by main offence: drug offences in percent

EMCDDA Conference Lisbon 6-8 May 2009 Spread of HCV among Prisoners  High risk behaviour and high risk environment: HCV-prevalence 50-90%  Poor understanding of HCV dynamics  Unsafe injecting common  Tattooing widespread  Sharing of razors etc.

EMCDDA Conference Lisbon 6-8 May 2009 Prison are high risk environments  Loss of health protective means  High risk of overdose after release  Self harm over-represented  Discontinuation of treatment  Sexual violence (underreporting)

EMCDDA Conference Lisbon 6-8 May 2009 Health Consequences for prisoners  drug related deaths after release  suicide attempts  self harm  drug use related diseases are manifold higher than outside prisons walls  unsafe injections, sexual practices, tattooing and piercing

EMCDDA Conference Lisbon 6-8 May 2009 Health Consequences for prison staff  Risk of infections with blood borne diseases while searching cells or by accidental needle stick injuries  Violence  Lack of understanding of addiction

EMCDDA Conference Lisbon 6-8 May 2009 Knowledge and Attitudes of prison staff … lack of staff (88,6%) … lack of safety for prison staff (46,5%) … Overcrouding = Problem (62,8%) … lack of information on infectious diseases (44,7%) … high infections risk Hepatitis B/C, TB, HIV (42-50%) … Violence among prisones (98,3%) Against the introduction of HR measures: needles and syringes: 67% steril tattooing eqipement: 79%

EMCDDA Conference Lisbon 6-8 May 2009 Transmission of Blood- Borne-Viruses in Prisons  HIV outbreaks  Transmission of HCV/HBV  Imprisonment independent predictor for HCV  Tattooing/piercing

EMCDDA Conference Lisbon 6-8 May 2009 EC Council Recommendation???  Impact assessment done in 2008  Specific and operational objectives on –Prevention –Treatment –Harm reduction –Reintegration –Monitoring/analysis of drug use among prisoners

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: Prevention (1/2)  Improving education, information and communication –tailor-made prevention material (e.g. youth, migrants, women) –Provide accurate and non-judgemental information –Increase the knowledge, attitudes and skills of both prisoners and staff with regard to drug use, drug related infectious diseases, drug injecting, STIs, tattooing and piercing  Tackle the problem of physical, psychological and sexual violence around drug trafficking, consumption and sexual contacts

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: Prevention (2/2)  Provide internal and external counselling in order to promote risk reduction and to facilitate access to appropriate treatment, care and support services  Involve NGOs (confidential partners for sensitive topics like unprotected sex, illicit drug use)  Integrate families and communities in prevention strategies (very important in the period before and after release, maintenance of achievements)

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: Treatment (1/2)  Offering diversity of counselling, treatment, care, and support (social services, drug-care units, drug counselling and drug treatment services)  Improved Strategies of “therapy instead of punishment”  Motivational interventions (offered by professionals inside or outside prisons or peers) help to increase motivation for change and compliance with treatment regime

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: Treatment (2/2)  Reduction of drug related morbidity and mortality by improved screening and treatment of infectious diseases  Reduction of overdose mortality (reference to community treatment facilities on release, overdose prevention activities before release)  Offer protected environment (e.g. drug free units) to motivated drug users

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: HR (1/2)  Access to evidence based measures to reduce the prevalence and incidence of BB infections –“safer use” training facilitated by information –safer use kits containing sterile injection material, disinfectants and instructions how to use them –syringe/needle exchange programmes  Support safer sex –information material –easily accessible condoms and lubricants –possibility of conjugal visits for inmates with their spouses/ partners

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: HR (2/2)  Improvement of voluntary testing opportunities (HIV, hep, STDs, TB), stick to personality rights and data protection rules  Free vaccination for prisoners and staff  Reduce drug related mortality by implementation of measures to reduce morbidity, and the risks of overdose deaths (drug treatment opportunities which minimise uncontrolled use, relapse prevention interventions after detoxification, staff competence to apply resuscitation in case of acute overdosing).  Reduce intravenous drug use and needle sharing by offering substitution maintenance treatment for all IDUs in prison

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: Reintegration (1/1)  Connect prison drug services with community services  Seamless provision of care after release: improve collaboration between prison and community health care services  Involve NGO services already during prison sentence in care and treatment planning

EMCDDA Conference Lisbon 6-8 May 2009 Operational Objectives: Monitoring (1/1)  Standards for monitoring, documentation, analysis and reporting on prevalence, incidence and trends of drug use, infectious diseases and related risk behaviours inside prisons should be developed and implemented in all EU MS.  Standards should be developed on EU level (i.e. a common EU protocol and instruments which allow collecting comparable and reliable data)  A standard protocol including a standard questionnaire and methodological and ethical recommendations about how to implement a prison survey on health and drug-related issues.

EMCDDA Conference Lisbon 6-8 May 2009 Need for research  Epidemiology of infec. diseases and health risks in the prison setting (cross sectional and longitudinal)  Identifying key figures for a monitoring system  Evaluation of the long-term effects of interventions and derivation of ‘Good Practice’  In-prison treatment and intervention monitoring: what works and why?  Obstacles of transfer of harm reduction measures into the prison setting  Cost effectiveness and cost benefit of in-prison and throughcare programmes  Better understanding of drug use patterns (drugs, frequency, amounts, routes of administration)  qualitative research

EMCDDA Conference Lisbon 6-8 May 2009 EU and MS policy  Acknowledgement of the prisons as priority settings for effective health responses  Continuous development of alternatives to imprisonment  Need for comparable and reliable information on situation and responses to drug use in prison  Promotion of exchange of good practice between MS  Closing the ‘treatment gap’ to prevent undermining health gains achieved in the community (prisons can provide opportunity for effective interventions)

EMCDDA Conference Lisbon 6-8 May 2009

Under development  UNODC Toolkit for HIV Situation and Needs Assessment in Prison Settings  Draft will be out for field testing end of May 2009

EMCDDA Conference Lisbon 6-8 May 2009 SANCO funded project

EMCDDA Conference Lisbon 6-8 May 2009 DG JLS funded Project On the Outside: Continuity of care for people leaving prison Sainsbury Centre for Mental Health 2008

EMCDDA Conference Lisbon 6-8 May 2009 Good prison health is good public health ! Thanks for your attention!